Since Novartis published the first SHP2 allosteric inhibitor SHP099 in 2016, the discovery of other SHP2 inhibitors has ignited explosively. By May 2023, more than 14 SHP2 inhibitors are under clinical trials. The disclosed structures of several SHP2 inhibitors, besides Novartis’ clinical candidate TNO155, indicate that they have adopted SHP099 as the lead compound.
